Nevertheless, the tremendous works in this field have given us confidence that we are on track to provide an in-house solution to a particular clinical question in our practice: How to identify non-responders in a cohort of NSCLC patients with high PD-L1 expression prior to initiating the first-line pembrolizumab monotherapy? The gene discussed is CD274; the disease is non-small cell lung carcinoma.